Diagnosis and treatment of pediatric psoriasis: Current and future

American Journal of Clinical Dermatology

Volumn 14, Issue 3, 2013, Pages 195-213

  Shah, Kara N ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; EMOLLIENT AGENT; ETANERCEPT; ETRETIN; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 23; ISOTRETINOIN; METHOTREXATE; PIMECROLIMUS; RETINOIC ACID; RETINOID; SALICYLIC ACID; TACROLIMUS; TAZAROTENE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; ULOBETASOL PROPIONATE; UNINDEXED DRUG; USTEKINUMAB; VITAMIN D DERIVATIVE;

ACNE; ADAPTIVE IMMUNITY; APHTHOUS STOMATITIS; ATOPIC DERMATITIS; BONE MARROW SUPPRESSION; CATARACT; CELL PROLIFERATION; CHEILITIS; CHILDHOOD DISEASE; CLINICAL FEATURE; CONTACT DERMATITIS; CUSHING SYNDROME; DEPRESSION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; ERYTHRODERMIC PSORIASIS; EXCIMER LASER; EYE TOXICITY; FATIGUE; FOLLICULITIS; GINGIVA HYPERPLASIA; GLAUCOMA; GROWTH RETARDATION; GUTTATE PSORIASIS; HAIR LOSS; HIRSUTISM; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPEROSTOSIS; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOMAGNESEMIA; INFECTION; INJECTION SITE REACTION; INNATE IMMUNITY; INTERSTITIAL PNEUMONIA; INTRAOCULAR PRESSURE; LIVER FUNCTION; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT EDUCATION; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIASIS VULGARIS; PSYCHOSOCIAL CARE; PURPURA; PUSTULAR PSORIASIS; PUSTULOSIS PALMOPLANTARIS; PUVA; PYOGENIC GRANULOMA; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN BIOPSY; SKIN FRAGILITY; SKIN IRRITATION; STRIA; TELANGIECTASIA; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ALGORITHMS; CHILD; DERMATOLOGIC AGENTS; HUMANS; PHOTOTHERAPY; PSORIASIS;

EID: 84878750488     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0026-8     Document Type: Review

References (165)

1. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermtol. 1985;13(3):450-6.
2. Fan X, Xiao FL, Yang S, et al. Childhood psoriasis: a study of 277 patients from China. JEADV. 2007;21(6):762-5.
3. Henseler T. The genetics of psoriasis. J Am Acad Dermatol. 1997;37(2 Pt 3):S1-11.
4. Farber EM, Nall ML. Epidemiology: natural history and genetics. In: Roienigk HH, Maibach HI, editors. Psoriasis. 3rd ed. New York: Marcel Dekker; 1998. p. 107-58.
5. Kumar B, Jain R, Sandhu K, et al. Epidemiology of childhood psoriasis: a study of 419 patients from northern India. Int J Dermatol. 2004;43(9):654-8.
6. Kwon HH, Na SJ, Jo SJ, et al. Epidemiology and clinical features of pediatric psoriasis in tertiary referral psoriasis clinic. J Dermatol. 2012;39(3):260-4.
7. Tollefson MM, Crowson CS, McEvoy MT, et al. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979-87.
8. Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148(1):1-18.
9. Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol. 2000;17(3):174-8.
10. Neville EA, Finn OA. Psoriasiform napkin dermatitis: a follow-up study. Br J Dermatol. 1975;92(3):279-85.
11. Farber EM, Mullen RH, Jacobs AH, et al. Infantile psoriasis: a follow-up study. Pediatr Dermatol. 1986;3(3):237-43.
12. Boje Rasmussen H, Hagdrup H, Schmidt H. Psoriasiform napkin dermatitis. Acta Derm Venereol. 1986;66(6):534-6.
13. Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011;23(5):437-43.
14. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53(4):573.
15. Ramsey SE, Bolaria RK, Cabral DA, et al. Comparison of criteria for the classification of childhood arthritis. J Rheumatol. 2000;27(5):1283-6.
16. Stoll ML, Nigrovic PA, Gotte AC, et al. Clinical comparison of early-onset psoriatic and non-psoriatic oligoarticular juvenile idiopathic arthritis. Clin Exp Rheumatol. 2011;29(3):582-8.
17. Augustin M, Glaeske G, Radtke MA, et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633-6.
18. Au SC, Goldminz AM, Loo DS, et al. Association between pediatric psoriasis and the metabolic syndrome. J Am Acad Dermatol. 2012;66(6):1012-3.
19. Koebnick C, Black MH, Smith N, et al. The association of psoriasis and elevated blood lipids in overweight and obese children. J Pediatr. 2011;159(4):577-83.
20. Volf EM, Levine DE, Michelon MA, et al. Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts. J Drugs Dermatol. 2011;10(8):900-1.
21. Zamberk P, Velazquez D, Campos M, et al. Paediatric psoriasis: narrowband UVB treatment. JEADV. 2010;24(4):415-9.
22. Bilgic A, Bilgic O, Akis HK, et al. Psychiatric symptoms and health-related quality of life in children and adolescents with psoriasis. Pediatr Derm. 2010;27(6):614-7.
23. Varni JW, Globe DR, Gandra SR, et al. Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseases. Eur J Pediatr. 2012;171(3):485-92.
24. Michalak-Stoma A, Pietrzak A, Szepietowski JC, et al. Cytokine network in psoriasis revisited. Eur Cytokine Netw. 2011;22(4):160-8.
25. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78(5):827-51.
26. Mallon E, Bunce M, Savoie H, et al. HLA-C and guttate psoriasis. Br J Dermatol. 2000;143(6):1177-82.
27. Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90(5):784-95.
28. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. New Engl J Med. 2011;365(7):620-8.
29. Rahman P, Elder JT. Genetics of psoriasis and psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39(2):431-3.
30. Chandran V. The genetics of psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;14(2):149-56.
31. Ozden MG, Tekin NS, Gurer MA, et al. Environmental risk factors in pediatric psoriasis: a multicenter case-control study. Pediatr Dermatol. 2011;28(3):306-12.
32. Rasmussen JE. The relationship between infection with group A beta hemolytic streptococci and the development of psoriasis. Pediatr Infect Dis J. 2000;19(2):153-4.
33. Leung DY, Travers JB, Giorno R, et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J Clin Invest. 1995;96(5):2106-12.
34. Honig PJ. Guttate psoriasis associated with perianal streptococcal disease. J Pediatr. 1988;113(6):1037-9.
35. Owen CM, Chalmers RJ, O'Sullivan T, et al. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database Syst Rev. 2000;2:CD001976.
36. Eberhard BA, Sundel RP, Newburger JW, et al. Psoriatic eruption in Kawasaki disease. J Pediatr. 2000;137(4):578-80.
37. Han MH, Jang KA, Sung KJ, et al. A case of guttate psoriasis following Kawasaki disease. Br J Dermatol. 2000;142(3):548-50.
38. Kishimoto S, Muneuchi J, Takahashi Y, et al. Psoriasiform skin lesion and supprative acrodermatitis associated with Kawasaki disease followed by the treatment with infliximab: a case report. Acta Paediatr. 2010;99(7):1102-4.
39. Liao YC, Lee JY. Psoriasis in a 3-month-old infant with Kawasaki disease. Dermatol Online J. 2009;15(11):10.
40. Ergin S, Karaduman A, Demirkaya E, et al. Plaque psoriasis induced after Kawasaki disease. Turk J Pediatr. 2009;51(4):375-7.
41. Yoon SY, Oh ST, Lee JY, et al. Plaque type psoriasiform eruption following Kawasaki disease. Pediatr Dermatol. 2007;24(3):336-7.
42. Yoon SY, Oh ST, Lee JY, et al. A plaque type psoriasiform eruption following Kawasaki disease. Pediatr Dermatol. 2007;24(1):96-8.
43. Mizuno Y, Suga Y, Muramatsu S, et al. Psoriasiform and palmoplanter pustular lesions induced after Kawasaki disease. Int J Dermatol. 2006;45(9):1080-2.
44. Menni S, Gualandri L, Boccardi D, et al. Association of psoriasis-like eruption and Kawasaki disease. J Dermatol. 2006;33(8):571-3.
45. Tsai HJ, Wu WM, Chang YC, et al. Annular pustules in Kawasaki disease: a further case indicating the association with psoriasis? Cutis. 2003;72(5):354-6.
46. Zvulunov A, Greenberg D, Cagnano E, et al. Development of psoriatic lesions during acute and convalescent phases of Kawasaki disease. J Paediatr Child Health. 2003;39(3):229-31.
47. Garty B, Mosseri R, Finkelstein Y. Guttate psoriasis following Kawasaki disease. Pediatr Dermatol. 2001;18(6):507-8.
48. Rogers M. Childhood psoriasis. Curr Opin Pediatr. 2002;14(4):404-9.
49. Howard R, Tsuchiya A. Adult skin disease in the pediatric patient. Dermatol Clin. 1998;16(3):593-608.
50. Morris A, Rogers M, Fischer G, et al. Childhood psoriasis: a clinical review of 1262 cases. Pediatr Dermatol. 2001;18(3):188-98.
51. Nanda A, Kaur S, Kaur I, et al. Childhood psoriasis: an epidemiologic survey of 112 patients. Pediatr Dermatol. 1990;7(1):19-21.
52. al-Fouzan AS, Nanda A. A survey of childhood psoriasis in Kuwait. Pediatr Dermatol. 1994;11(2):116-9.
53. Hutton KP, Orenberg EK, Jacobs AH. Childhood psoriasis. Cutis. 1987;39(1):26-7.
54. Rasmussen JE. Psoriasis in children. Dermatol Clin. 1986;4(1):99-106.
55. Nyfors A, Lemholt K. Psoriasis in children: a short review and a survey of 245 cases. Br J Dermatol. 1975;92(4):437-42.
56. Herbst RA, Hoch O, Kapp A, et al. Guttate psoriasis triggered by perianal streptococcal dermatitis in a four-year-old boy. J Am Acad Dermatol. 2000;42(5 Pt 2):885-7.
57. Nyfors A. Psoriasis in children: characteristics, prognosis and therapy: a review. Acta Derm Venereol Suppl (Stockh). 1981;95:47-53.
58. Tervaert WC, Esseveld H. A study of the incidence of haemolytic streptococci in the throat in patients with psoriasis vulgaris, with reference to their role in the pathogenesis of this disease. Dermatologica. 1970;140(5):282-90.
59. Whyte HJ, Baughman RD. Acute guttate psoriasis and streptococcal infection. Arch Dermatol. 1964;89:350-6.
60. Telfer NR, Chalmers RJ, Whale K, et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol. 1992;128(1):39-42.
61. Cordoro KM. Management of childhood psoriasis. Adv Dermatol. 2008;24:125-69.
62. Trueb RM. Therapies for childhood psoriasis. Curr Probl Dermatol. 2009;38:137-59.
63. Nanda A. Concomitance of psoriasis and atopic dermatitis. Dermatology. 1995;191(1):72.
64. Lever WF, Elder DE. Lever's histopathology of the skin. 10th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2009.
65. Murphy M, Kerr P, Grant-Kels JM. The histopathologic spectrum of psoriasis. Clin Dermatol. 2007;25(6):524-8.
66. Vogel SA, Yentzer B, Davis SA, et al. Trends in pediatric psoriasis outpatient health care delivery in the United States. Arch Dermatol. 2012;148(1):66-71.
67. Lewkowicz D, Gottlieb AB. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther. 2004;17(5):364-75.
68. Bhutani T, Kamangar F, Cordoro KM. Management of pediatric psoriasis. Pediatr Ann. 2012;41(1):e1-7.
69. de Jager ME, de Jong EM, van de Kerkhof PC, et al. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol. 2010;62(6):1013-30.
70. Lara-Corrales I, Xi N, Pope E. Childhood psoriasis treatment: evidence published over the last 5 years. Rev Recent Clin Trials. 2011;6(1):36-43.
71. Gelmetti C. Therapeutic moisturizers as adjuvant therapy for psoriasis patients. Am J Clin Dermatol. 2009;10(Suppl. 1):7-12.
72. Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol. 1991;25(6 Pt 2):1166-9.
73. Kimball AB, Gold MH, Zib B, et al. Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents. J Am Acad Dermatol. 2008;59(3):448-54, 454.e1.
74. Ahn SJ, Oh SH, Chang SE, et al. A case of infantile psoriasis with pseudoainhum successfully treated with topical pimecrolimus and low-dose narrowband UVB phototherapy. JEADV. 2006;20(10):1332-4.
75. Amichai B. Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream. JEADV. 2004;18(6):742-3.
76. Mansouri P, Farshi S. Pimecrolimus 1 percent cream in the treatment of psoriasis in a child. Dermatol Online J. 2006;12(2):7.
77. Brune A, Miller DW, Lin P, et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24(1):76-80.
78. Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol. 2005;53(4):713-6.
79. Choi YJ, Hann SK, Chang SN, et al. Infantile psoriasis: successful treatment with topical calcipotriol. Pediatr Dermatol. 2000;17(3):242-4.
80. Darley CR, Cunliffe WJ, Green CM, et al. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol. 1996;135(3):390-3.
81. Oranje AP, Marcoux D, Svensson A, et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol. 1997;36(2 Pt 1):203-8.
82. Park SB, Suh DH, Youn JI. A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Pediatr Dermatol. 1999;16(4):321-5.
83. Patrizi A, Neri I, Rizzoli L, et al. Topical calcipotriol in childhood psoriasis. Acta Derm Venereol. 1999;79(6):477.
84. Perez A, Chen TC, Turner A, et al. Pilot study of topical calcitriol (1,25-dihydroxyvitamin D3) for treating psoriasis in children. Arch Dermatol. 1995;131(8):961-2.
85. Saggese G, Federico G, Battini R. Topical application of 1,25-dihydroxyvitamin D3 (calcitriol) is an effective and reliable therapy to cure skin lesions in psoriatic children. Eur J Pediatr. 1993;152(5):389-92.
86. Travis LB, Silverberg NB. Psoriasis in infancy: therapy with calcipotriene ointment. Cutis. 2001;68(5):341-4.
87. Comaish JS. Tar and related compounds in the therapy of psoriasis. Clin Exp Dermatol. 1981;6(6):639-45.
88. Lin AN, Moses K. Tar revisited. Int J Dermatol. 1985;24(4):216-8.
89. Borska L, Fiala Z, Krejsek J, et al. Immunologic changes in TNF-alpha, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol. 2007;24(6):607-12.
90. Kortuem KR, Davis MD, Witman PM, et al. Results of Goeckerman treatment for psoriasis in children: a 21-year retrospective review. Pediatr Dermatol. 2010;27(5):518-24.
91. Menter MA, Whiting DA, McWilliams J. Resistant childhood psoriasis: an analysis of patients seen in a day-care center. Pediatr Dermatol. 1984;2(1):8-12.
92. Borska L, Andrys C, Krejsek J, et al. Genotoxic hazard and cellular stress in pediatric patients treated for psoriasis with the Goeckerman regimen. Pediatr Dermatol. 2009;26(1):23-7.
93. Diluvio L, Campione E, Paterno EJ, et al. Childhood nail psoriasis: a useful treatment with tazarotene 0.05%. Pediatr Dermatol. 2007;24(3):332-3.
94. Zvulunov A, Anisfeld A, Metzker A. Efficacy of short-contact therapy with dithranol in childhood psoriasis. Int J Dermatol. 1994;33(11):808-10.
95. Guerrier CJ, Porter DI. An open assessment of 0.1% dithranol in a 17% urea base ('Psoradrate' 0.1%) in the treatment of psoriasis of children. Curr Med Res Opin. 1983;8(6):446-50.
96. Pavlovsky M, Baum S, Shpiro D, et al. Narrow band UVB: is it effective and safe for paediatric psoriasis and atopic dermatitis? JEADV. 2011;25(6):727-9.
97. al-Fouzan AS, Nanda A. UVB phototherapy in childhood psoriasis. Pediatr Dermatol. 1995;12(1):66.
98. Pasic A, Ceovic R, Lipozencic J, et al. Phototherapy in pediatric patients. Pediatr Dermatol. 2003;20(1):71-7.
99. Tay YK, Morelli JG, Weston WL. Experience with UVB phototherapy in children. Pediatr Dermatol. 1996;13(5):406-9.
100. Jain VK, Aggarwal K, Jain K, et al. Narrow-band UV-B phototherapy in childhood psoriasis. Int J Dermatol. 2007;46(3):320-2.
101. Pahlajani N, Katz BJ, Lozano AM, et al. Comparison of the efficacy and safety of the 308 nm excimer laser for the treatment of localized psoriasis in adults and in children: a pilot study. Pediatr Dermatol. 2005;22(2):161-5.
102. Gelfand JM, Wan J, Callis Duffin K, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012;148(4):487-94.
103. Patel RV, Clark LN, Lebwohl M, et al. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6):1001-17.
104. Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64(4):1263-71.
105. Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67(2):279-88.
106. Kopp T, Karlhofer F, Szepfalusi Z, et al. Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type. Br J Dermatol. 2004;151(4):912-6.
107. de Oliveira ST, Maragno L, Arnone M, et al. Generalized pustular psoriasis in childhood. Pediatr Dermatol. 2010;27(4):349-54.
108. Xiao T, Li B, He CD, et al. Juvenile generalized pustular psoriasis. J Dermatol. 2007;34(8):573-6.
109. Juanqin G, Zhiqiang C, Zijia H. Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases. Pediatr Dermatol. 1998;15(2):144-6.
110. Chao PH, Cheng YW, Chung MY. Generalized pustular psoriasis in a 6-week-old infant. Pediatr Dermatol. 2009;26(3):352-4.
111. Salleras M, Sanchez-Regana M, Umbert P. Congenital erythrodermic psoriasis: case report and literature review. Pediatr Dermatol. 1995;12(3):231-4.
112. Judge MR, McDonald A, Black MM. Pustular psoriasis in childhood. Clin Exp Dermatol. 1993;18(2):97-9.
113. Ergin S, Ersoy-Evans S, Sahin S, et al. Acitretin is a safe treatment option for infantile pustular psoriasis. J Dermatol Treat. 2008;19(6):341-3.
114. Rosinska D, Wolska H, Jablonska S, et al. Etretinate in severe psoriasis of children. Pediatr Dermatol. 1988;5(4):266-72.
115. Karamfilov T, Wollina U. Juvenile generalized pustular psoriasis. Acta Derm Venereol. 1998;78(3):220.
116. Shelnitz LS, Esterly NB, Honig PJ. Etretinate therapy for generalized pustular psoriasis in children. Arch Dermatol. 1987;123(2):230-3.
117. Liao PB, Rubinson R, Howard R, et al. Annular pustular psoriasis: most common form of pustular psoriasis in children: report of three cases and review of the literature. Pediatr Dermatol. 2002;19(1):19-25.
118. Al-Shobaili H, Al-Khenaizan S. Childhood generalized pustular psoriasis: successful treatment with isotretinoin. Pediatr Dermatol. 2007;24(5):563-4.
119. Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2009;60(5):824-37.
120. Kumar B, Dhar S, Handa S, et al. Methotrexate in childhood psoriasis. Pediatr Dermatol. 1994;11(3):271-3.
121. Dogra S, Handa S, Kanwar AJ. Methotrexate in severe childhood psoriasis. Pediatr Dermatol. 2004;21(3):283-4.
122. Dogra S, Kumaran MS, Handa S, et al. Methotrexate for generalized pustular psoriasis in a 2-year-old child. Pediatr Dermatol. 2005;22(1):85-6.
123. Kalla G, Goyal AM. Juvenile generalized pustular psoriasis. Pediatr Dermatol. 1996;13(1):45-6.
124. Kaur I, Dogra S, De D, et al. Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from India. Pediatr Dermatol. 2008;25(2):184-8.
125. Garg T, Chander R, Mittal S. Familial juvenile generalized pustular psoriasis: response to methotrexate. Skinmed. 2011;9(3):190-1.
126. Collin B, Vani A, Ogboli M, et al. Methotrexate treatment in 13 children with severe plaque psoriasis. Clin Exp Dermatol. 2009;34(3):295-8.
127. Scott RB, Surana R. Erythrodermic psoriasis in childhood: a young Negro child treated with methotrexate. Am J Dis Child. 1968;116(2):218-21.
128. Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62(4):655-62.
129. Pereira TM, Vieira AP, Fernandes JC, et al. Cyclosporin A treatment in severe childhood psoriasis. JEADV. 2006;20(6):651-6.
130. Perrett CM, Ilchyshyn A, Berth-Jones J. Cyclosporin in childhood psoriasis. J Dermatol Treat. 2003;14(2):113-8.
131. Kilic SS, Hacimustafaoglu M, Celebi S, et al. Low dose cyclosporin A treatment in generalized pustular psoriasis. Pediatr Dermatol. 2001;18(3):246-8.
132. Alli N, Gungor E, Karakayali G, et al. The use of cyclosporin in a child with generalized pustular psoriasis. Br J Dermatol. 1998;139(4):754-5.
133. Kim HS, Kim GM, Kim SY. Two-stage therapy for childhood generalized pustular psoriasis: low-dose cyclosporin for induction and maintenance with acitretin/narrowband ultraviolet B phototherapy. Pediatr Dermatol. 2006;23(3):306-8.
134. Nakamura S, Hashimoto Y, Igawa S, et al. Childhood generalized pustular psoriasis treated by preprandial ciclosporin administration: serum cytokine pattern during the course of the disease. Clin Exp Dermatol. 2009;34(8):e1023-4.
135. Mahe E, Bodemer C, Pruszkowski A, et al. Cyclosporine in childhood psoriasis. Arch Dermatol. 2001;137(11):1532-3.
136. Marji JS, Marcus R, Moennich J, et al. Use of biologic agents in pediatric psoriasis. J Drugs Dermatol. 2010;9(8):975-86.
137. Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol. 2010;6(10):561-71.
138. Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035-50.
139. Pontikaki I, Shahi E, Frasin LA, et al. Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2012;42(2):131-4.
140. Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012;66(5):742-51.
141. Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012;166(4):861-72.
142. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144(2):200-7.
143. Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012;132(2):304-14.
144. Strober BE, Crowley JJ, Yamauchi PS, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):661-8.
145. Gottlieb AB, Leonardi C, Kerdel F, et al. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011;165(3):652-60.
146. Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol. 2011;12(2):113-25.
147. Hawrot AC, Metry DW, Theos AJ, et al. Etanercept for psoriasis in the pediatric population: experience in nine patients. Pediatr Dermatol. 2006;23(1):67-71.
148. Kress DW. Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl. 2):S126-8.
149. Papoutsaki M, Costanzo A, Mazzotta A, et al. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol. 2006;154(1):181-3.
150. Safa G, Loppin M, Bousser AM, et al. Etanercept in a 7-year-old boy with severe and recalcitrant psoriasis. J Am Acad Dermatol. 2007;56(2 Suppl.):S19-20.
151. Fabrizi G, Guerriero C, Pagliarello C. Etanercept in infants: suberythrodermic, recalcitrant psoriasis in a 22 month-old child successfully treated with etanercept. Eur J Dermatol. 2007;17(3):245.
152. Floristan U, Feltes R, Ramirez P, et al. Recalcitrant palmoplantar pustular psoriasis treated with etanercept. Pediatr Dermatol. 2011;28(3):349-50.
153. Pereira TM, Vieira AP, Fernandes JC, et al. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology. 2006;213(4):350-2.
154. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. New Engl J Med. 2008;358(3):241-51.
155. Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol. 2010;63(5):762-8.
156. Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatol Treat. 2005;16(5-6):350-2.
157. Alvarez AC, Rodriguez-Nevado I, De Argila D, et al. Recalcitrant pustular psoriasis successfully treated with adalimumab. Pediatr Dermatol. 2011;28(2):195-7.
158. Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol. 2004;21(1):87-8.
159. Farnsworth NN, George SJ, Hsu S. Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol Online J. 2005;11(3):11.
160. Rott S, Kuster RM, Mrowietz U. Successful treatment of severe psoriatic arthritis with infliximab in an 11-year-old child suffering from linear psoriasis along lines of Blaschko. Br J Dermatol. 2007;157(1):191-2.
161. Perman MJ, Lovell DJ, Denson LA, et al. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children. Pediatr Dermatol. 2012;29(4):454-9.
162. Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52(2):230-2.
163. Pourciau C, Shwayder T. Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab. Pediatr Dermatol. 2010;27(5):539-40.
164. Stuart P, Malick F, Nair RP, et al. Analysis of phenotypic variation in psoriasis as a function of age at onset and family history. Arch Dermatol Res. 2002;294(5):207-13.
165. Ferrandiz C, Pujol RM, Garcia-Patos V, et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol. 2002;46(6):867-73.